Anormed news from FierceBiotech

Genzyme is laying claim to the keys to Bioenvision after winning shareholders' approval of the $345 million buyout. SCO Capital Partners, which owns 13 percent of Bioenvision, had Read more...

Shares of Genzyme were buoyed slightly by the news that Mozobil hit primary and secondary goals in a late-stage trial for non-Hodgkin's lymphoma. The drug spurs the release of bone marrow stem cells Read more...

San Diego-based Orexigen Therapeutics has completed a $30 million Series C private equity financing. The deal was financed by new investors MPM BioEquities and Wasatch Advisors, along with existing investors. The money will be used to support the company's clinical programs for its two lead drug candidates: Contrave, currently in Phase II/III trials, and Excalia, which is in Phase IIb. Orexigen is involved in developing therapies for the treatment of obesity.

- check out Orexigen's …

Read more...

Lilly buys Icos in $2.1B deal

Read more...

> AnorMED has completed enrollment in a phase III trial of Mozobil for cancer patients. Release

> Orexigen Therapeutics has revealed positive Phase II results for Excalia, for the treatment of obesity. Excalia is a combination of two centrally-acting medications.  Release

> SkinMedica has received FDA approval for Desonate, …

Read more...

It looks like that Genzyme has won the battle to acquire Canada's AnorMed. AnorMed's board has approved Genzyme's offer of $13.50 a share, which values the company at $580 million. That's $200 million more than Genzyme first offered and significantly higher than the $515 million offered by Millennium Pharmaceuticals in a competing bid. Millennium has bowed out of the bidding, but says it's owed $19.5 million under the terms of its pact with AnorMED. The deal will net Genzyme AnorMed's …

Read more...

The bidding war for Canada's AnorMED is far from over. The company 's board announced that Genzyme's sweetened offer of $13.50 a share--or $580 million--was superior to Millennium's bid. AnorMED gave Millennium three days to match or beat the Genzyme bid. If it does, AnorMED says they'll go with Millennium. If it doesn't, AnorMED will sign on to Genzyme's offer. Genzyme got the bidding war going with its unsolicited offer of $380 million.

- check out the AFX …

Read more...

Genzyme has announced it is willing to offer $13.50 a share for AnorMED in a deal valued at $580 million. That's $200 million more than it offered a few weeks ago and $65 million higher than the offer from Millennium Pharmaceuticals, which AnorMED has recommended to investors. Genzyme's seriously sweetened offer is contingent on AnorMED's support. AnorMED's board swiftly rejected Genzyme's original offer in September, noting that it felt the $8.55 bid significantly undervalued the …

Read more...

Genzyme is displaying fresh signs that it won't give up on its bid to acquire AnorMED. AnorMED says that Genzyme has signaled its interest in upping its bid past the $12 a share offer from Millennium. And having triggered a bidding war, AnorMED has indicated that its interest now is in boosting shareholder value and notes that Millennium will have a chance to counter any sweetened offer made by Genzyme. Genzyme set off the bidding war with its offer to buy AnorMED for $8.55 a share, a …

Read more...

Merck KGaA buys Serono for $13.3B

Read more...